---
title: "Aurora Cannabis Faces Shareholder Activism Ahead of Crucial 2025 Meeting"
description: "Aurora Cannabis Inc. is preparing for its annual general and special meeting on August 8, 2025, urging shareholders to vote before the August 6 proxy deadline. The Board recommends support for all dir"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250768070.md"
published_at: "2025-07-30T11:05:30.000Z"
---

# Aurora Cannabis Faces Shareholder Activism Ahead of Crucial 2025 Meeting

> Aurora Cannabis Inc. is preparing for its annual general and special meeting on August 8, 2025, urging shareholders to vote before the August 6 proxy deadline. The Board recommends support for all director nominees and resolutions. Meeting materials are available on the company's website and SEDAR+. Aurora has partnered with Laurel Hill Advisory Group to assist shareholders with voting inquiries, emphasizing the significance of every vote.

Aurora Cannabis Inc., a leading Canada-based global medical cannabis company, is engaging its shareholders in anticipation of its upcoming annual general and special meeting, scheduled to take place on August 8, 2025, at 1:00 p.m. Eastern Time via live webcast. The company is urging its shareholders to participate in the voting process well ahead of the proxy voting deadline set for August 6, 2025. Aurora’s Board of Directors has recommended shareholders to support all director nominees and proposed resolutions. The company has made meeting materials accessible on its website and SEDAR+ for shareholders to review. Additionally, Aurora has partnered with Laurel Hill Advisory Group to provide assistance to shareholders who have questions or require help with the voting process, underscoring the importance of each shareholder’s vote regardless of the number of shares owned. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurora Cannabis Inc. published the original content used to generate this news brief via CNW (Ref. ID: C8689) on July 30, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [ACB.US - Aurora Cannabis](https://longbridge.com/en/quote/ACB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 极光大麻财报：第三季度概览 | Aurora Cannabis（纳斯达克代码：ACB）于 2026 年 2 月 4 日公布了第三季度财报，实际每股收益（EPS）为 0.021 美元，未能达到预期的 0.19 美元，差距达 89%。与去年同期相比，收入增加了 449 万美元 | [Link](https://longbridge.com/en/news/274813375.md) |
| 极光大麻公司发布 2026 年第三季度管理层讨论与分析（MD&A）报告 | Aurora Cannabis Inc. 发布了其 2026 年第三季度管理层讨论与分析报告，强调其在加拿大的医疗和消费大麻产品的生产、分销和销售，以及在欧盟，特别是德国的批发医疗大麻。该公司还在将其医疗大麻分销扩展到国际市场，包括澳大利亚 | [Link](https://longbridge.com/en/news/274811263.md) |
| Cannabix Technologies 宣布进行非经纪 LIFE 私募配售 | Cannabix Technologies Inc. 宣布进行一项非承销的私人配售，计划通过发行 1,000,000 到 2,000,000 个单位，每个单位价格为 0.50 加元，筹集 500,000 加元至 1,000,000 加元。每 | [Link](https://longbridge.com/en/news/275184611.md) |
| 极光大麻公司将抗白粉病大麻推进至生产试验阶段 | 极光大麻已在其 Aurora Ridge 设施推进了对白粉病抗性研究，宣布进行生产试验。该公司旨在通过遗传抗性源 PM2 增强疾病抗性，同时保持质量特性。这项工作已在多个会议上展示，目前在主要市场申请专利。尽管分析师对其给予持有评级，目标价 | [Link](https://longbridge.com/en/news/272555187.md) |
| 极光大麻宣布了一项新的市价增发股票计划，金额高达 1 亿美元 | Aurora Cannabis Inc. 宣布了一项新的市场发行计划，允许发行和销售最多 1 亿美元的普通股。所得款项将用于战略和增值目的，包括增加生产能力和潜在收购。这些股票将在与 TD Securities (USA) LLC 的分销协 | [Link](https://longbridge.com/en/news/274809352.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.